Study on therapeutic results of adefovir dipivoxil in patients with HbeAg positive chronic hepatitis

ABSTRACT

Background: Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic infectious diseases worldwide. HBV infection is very common in Thua Thien \ufffd?Hue. Objectives:. Our study is aimed to assess the efficacy and safety of Adefovir dipivoxil(ADV) in patients with HBeAg positive chronic hepatitis B .. Subjects and method: Design of study Prospective; 36 patients with HbeAg (+) chronic B hepatitis were enrolled in this study, all patients were treated with Adefovir dipivoxil in 24 months at Hue University Hospital from October 2004 to September 2006 . Results: The rate of normalization of ALAT is 50 % after 6 months, 66.66% after 12 months and 69.44% after 24 months. The rate of HbeAg seroconversion is 11.11 % after 12 months and 30.55% after 24 months. This rate is Significantly higher in group of patients having the activity of SePT between 5 - 10 normal (58.33%). The rate of phenotypic resistance is only 2.77% after 12 months and 8.33% after 24 months. The tolerance is generally good\r\n', u'even in long - term treatment and no complication of renal\r\n', u'insufficiency was found. Conclusion: ADV appears an effective and safe in patients with HBeAg(+) chronic hepatitis. \r\n', u'